Anti-Cyclin D1 antibody (Ab226977)
BCL1, PRAD1, CCND1, G1/S-specific cyclin-D1, B-cell lymphoma 1 protein, BCL-1 oncogene, PRAD1 oncogene, BCL-1
反应种属：Human, Dog, Cat
抗原名称：CCND1
应用：WB, ELISA, IF/ICC, IP
详细信息
免疫原Recombinant Full Length Protein corresponding to Human CCND1. P24385
宿主/亚型Rabbit / IgG
抗体类型Polyclonal
产品形式Liquid
纯化方式Affinity purification Immunogen
储存缓冲液pH: 7 Preservative: 0.025% Proclin 300 Constituents: PBS, 20% Glycerol (glycerin, glycerine)
储存条件运输条件: Blue Ice
推荐的短期储存时间: 1-2 weeks
推荐的短期储存条件: +4°C
推荐的长期储存条件: -20°C
储存信息: Avoid freeze / thaw cycle
无载体蛋白No
文献引用 (107)
CST4 promotes EMT and tumor progression in ovarian cancer via Wnt/β-catenin signaling.
CST4 通过 Wnt/β-catenin 信号通路促进卵巢癌的 EMT 和肿瘤进展。
JOSD2 inhibits angiotensin II-induced vascular remodeling by deubiquitinating and stabilizing SMAD7.
JOSD2 通过去泛素化和稳定 SMAD7 来抑制血管紧张素 II 诱导的血管重塑
A comprehensive pan-cancer analysis of LRFN4: its potential as a prognostic biomarker and therapeutic target for immunotherapy
对LRFN4进行全面的泛癌分析：其作为预后生物标志物和免疫治疗靶点的潜力
Raddeanin A exerts potent efficacy against non-small cell lung cancer by inhibiting cyclin-dependent kinase 6.
Raddeanin A 通过抑制细胞周期蛋白依赖性激酶 6 对非小细胞肺癌发挥强效作用
The LINC01094/miR-545-3p/SLC7A11 Signaling Axis Promotes the Development of Gastric Cancer by Regulating Cell Growth and Ferroptosis.
LINC01094/miR-545-3p/SLC7A11 信号轴通过调节细胞生长和铁死亡促进胃癌的发展。
MST1R-targeted therapy in the battle against gallbladder cancer
MST1R 靶向治疗在抗击胆囊癌中的应用
Down-regulation of ESRP2 inhibits breast cancer cell proliferation via inhibiting cyclinD1
ESRP2 下调通过抑制 cyclinD1 抑制乳腺癌细胞增殖
Inhibition of esophageal cancer progression through HACE1-TRIP12 interaction and associated RAC1 ubiquitination and degradation
通过 HACE1-TRIP12 相互作用和相关 RAC1 泛素化和降解抑制食管癌进展
A-to-I-edited miR-1251-5p restrains tumor growth and metastasis in lung adenocarcinoma through regulating TCF7-mediated Wnt signaling pathway
A-to-I 编辑的 miR-1251-5p 通过调控 TCF7 介导的 Wnt 信号通路抑制肺腺癌的肿瘤生长和转移
Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities
域特异性 p53 突变体通过不同的机制激活 EGFR，暴露出组织独立的治疗弱点
- 1
- 2
- 3
- 4
- 5
- 6
- 11